Building a better mouse model for MS

To date, every successful therapy for MS has been first successfully trialled in the existing experimental model of MS in the mouse, known as Experimental Autoimmune Encephalomyelitis (EAE). Nevertheless, this model has some significant restrictions in that it does not replicate the circumstances of disease initiation in humans and it also fails to replicate the multiple different immune targets (antigens) implicated in MS. EAE also does not model the involvement of B cells as seen in human MS.

In this project, Professor Baxter is proposing to develop a number of modifications to overcome these problems, in order to develop an improved platform for testing new MS therapies.

MS is associated with the production within the central nervous system (CNS) of antibodies (seen as oligoclonal IgG bands in cerebrospinal fluid). There is some evidence that the production of these antibodies may be driven by latent Epstein Barr Virus (EBV) infection of B-cells (the immune cells that produce antibodies) located in the brain and that this may initiate autoimmunity.

Professor Baxter will develop genetically modified mice that mimic the genetic susceptibility seen in people with MS. And, by introducing genes that make the mice susceptible to EBV (mice are not normally susceptible to EBV infection), he will attempt to mimic the effects of EBV infection of B cells in mice.

This project will directly test whether EBV, via its effect on B-cells, can initiate MS in individuals with a genetic susceptibility. If successful, it will also produce a spontaneous model of MS in which the autoimmune reactivity develops naturally against a range of CNS antigens, better simulating the situation observed in the human disease. Such a model could greatly improve the validity of preclinical studies of therapeutics designed to reduce relapses or modulate the severity of disease after onset.